Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8485547 | Vaccine | 2018 | 11 Pages |
Abstract
As an alternative to producing recombinant protein, we engineered successfully the Nm-OM to express M2 Truncated-Nm-MIP, but lipooligosaccharide-extraction with Na-DOC was contra-indicated. Our data suggest that a multi-component vaccine containing a select number of Nm- and Ng-MIP type proteins would be required to provide broad coverage of both pathogens.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
MarÃa Victoria Humbert, Myron Christodoulides,